Literature DB >> 15049339

The choice of proton pump inhibitor: does it matter?

Per M Hellström1, Sigurd Vitols.   

Abstract

Proton pump inhibitors are used at different dosages for the treatment of acid-related gastrointestinal disorders, such as gastro-oesophaeal reflux and peptic ulcer disease. Comparisons of four different proton pump inhibitors: lansoprazole, omeprazole, pantoprazole, and rabeprazole show that they all have similar potency and efficacy. Rabeprazole, however, displays a slightly more rapid onset of acid inhibition than the others; the clinical advantage of this seems limited. The S-isomer of omeprazole, esomeprazole, exhibits a somewhat higher potency than the other proton pump inhibitors. Reports supporting a clinical advantage of this property are not convincing. To conclude, all inhibitors seem comparable as regards inhibition of gastric acid secretion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15049339     DOI: 10.1111/j.1742-7843.2004.pto940302.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  10 in total

1.  Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.

Authors:  Céline Vidaillac; Jean Guillon; Corinne Arpin; Isabelle Forfar-Bares; Boubakar B Ba; Jean Grellet; Stéphane Moreau; Daniel-Henri Caignard; Christian Jarry; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

Review 2.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

3.  Management of esophageal symptoms following fundoplication.

Authors:  Gregory S Sayuk; Ray E Clouse
Journal:  Curr Treat Options Gastroenterol       Date:  2005-08

4.  Appropriateness of treatment recommendations for PPI in hospital discharge letters.

Authors:  Dirk Ahrens; Jean-François Chenot; Gesa Behrens; Thomas Grimmsmann; Michael M Kochen
Journal:  Eur J Clin Pharmacol       Date:  2010-08-06       Impact factor: 2.953

Review 5.  Insights into the future of gastric acid suppression.

Authors:  Kenneth R DeVault; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

Review 6.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?

Authors:  Kwong Ming Fock; Tiing Leong Ang; Lean Choo Bee; Edmund Jon Deon Lee
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 8.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

9.  Eudragit L/HPMCAS blend enteric-coated lansoprazole pellets: enhanced drug stability and oral bioavailability.

Authors:  Yu Fang; Guozheng Wang; Rong Zhang; Zhihua Liu; Zhenghua Liu; Xiaohui Wu; Deying Cao
Journal:  AAPS PharmSciTech       Date:  2014-03-05       Impact factor: 3.246

10.  A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).

Authors:  Evangelos Kalaitzakis; Einar Björnsson
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.